Stada will acquire 15 brands of OTC products from GlaxoSmithKline (GSK), the company said. The transaction will cover 40 countries, including Poland.
Coldrex and Cetebe in the portfolio of Stada
As part of the acquisition, Stada will purchase rights to OTC products in 40 markets, mainly in European countries, including France, Germany, Italy, Poland, Russia, Spain and Switzerland. The transaction will cover 15 products, but five of them generate half of the group’s revenue. These are Coldrex (cold), Cetebe (vitamin C), Mebucaine (sore throat), Venoruton (leg swelling, venous insufficiency) and Tavegyl (allergy). The transaction is to be finalised in the second quarter of 2020. Its value has not been disclosed.
It is worth noting that last year, Stada took over five brands of dermatological products from GSK – Ceridal, Eurax, Oilatum, Polytar and Savlon, as well as Tixylix, a pediatric cold medicine. That transaction covered Europe and selected countries in Asia and the Americas.
Stada is growing in OTC
Over the past few months, Stada has significantly strengthened its position in the over-the-counter (OTC) segment. In November 2019, the company announced the acquisition of the Czech company Walmark from Mid Europa Partners (we have written more about it here). In late 2019. Stada also acquired 20 Takeda products in Eastern Europe. The transaction, worth $660m, included 20 products, mainly OTC drugs (vitamins), dietary supplements and selected Rx brands (cardiology, diabetes, general medicine and respiratory tract). The acquisition concerned the markets of Russia, Georgia, Azerbaijan, Belarus, Kazakhstan and Uzbekistan.
Moments later, the Flock announced the acquisition of the pharmaceutical division of Biopharma, one of the leading manufacturers in Ukraine. The transaction included both Rx and OTC products. Its value was not disclosed, but it was one of the largest ever transactions in the pharmaceutical sector in Ukraine.